NHS issues vaccination warning for pregnant women over dangerous virus currently surging in Australia
Health chiefs say the Australian winter often predicts how viruses will spread in the UK, and already this year cases of respiratory syncytial virus (RSV) have steadily risen in many areas.
The virus, which is a common cause of coughs and colds, may also cause a chest infection called bronchiolitis.
Some people have a high risk of becoming seriously ill with it, including babies and adults over 75.
According to NHS England, RSV is a leading cause of infant deaths worldwide and a main cause of children being taken into hospital.
Last winter, almost 7,000 bed days in England were taken up by children with RSV.
NHS England is encouraging pregnant women to get a jab that protects against RSV so their babies are protected after birth.
Kate Brintworth, chief midwifery officer for NHS England, said: 'While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation.
'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.'
Yusra Osman says that when her son, Zakariya, was three months old, he developed bronchiolitis from the virus. He had a fever and was gasping for breath.
The 34-year-old, from north London, said: 'Everything was a blur, but I remember his chest was caving in and out and he was really struggling to catch his breath.'
Nurses found her son's oxygen levels were dangerously low.
Ms Osman, a student midwife, said: 'That was one of those things you don't want to hear as a mum. He was crying, and we kept trying to put an oxygen mask on, but he was fighting to get it off and didn't want to be touched.'
Zakariya, who is now seven, needed oxygen and a feeding tube in hospital.
'It's a mum's worst nightmare. Had the RSV vaccine been available then, I'd definitely have had it,' Ms Osman said.
The RSV vaccine was offered to pregnant women in England for the first time last September and health officials say it has since helped to protect more than 300,000 mothers and babies.
Pregnant mothers from 28 weeks onwards are eligible, as are adults aged 75 to 79.
In the coming weeks, NHS England is set to invite more than a million people to have a jab, before the season for infections, which starts in October.
Greta Hayward, consultant midwife at the UK Health Security Agency, said babies born in late summer or the autumn are most likely to be admitted to hospital with the virus.
'Hundreds of babies attend emergency departments each day for bronchiolitis through most of November and December,' she said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
'Grey's Anatomy' star diagnosed with Hashimoto's: What to know about the disease
"Grey's Anatomy" star Camilla Luddington recently revealed she has been diagnosed with Hashimoto's disease, an autoimmune disorder. The British actress, known for her role as Dr. Jo Wilson, shared the news on the "Call It What It Is" podcast in an episode aired on Wednesday, which she co-hosts with fellow "Grey's Anatomy" star Jessica Capshaw. 'Grey's Anatomy' star opens up about battle with postpartum anxiety, severe PMS disorder Luddington explained that, for some time, she had felt unusually tired and sluggish, often joking about being "slothy." However, she didn't consider that there might be a medical reason behind it. After finally completing routine blood work, Luddington received the surprising diagnosis. "My doctor was like, everything looks great except this one little thing," she recalled. The news hit her hard. "I remember hearing the words 'autoimmune disease' and thinking, 'What the f---?'" Luddington said, though she later learned that hypothyroidism caused by Hashimoto's disease is quite common. Capshaw asked how Luddington processed the news, and Luddington admitted that she had suspected something was wrong with her health. "You know what? I knew something was up," Luddington shared. "Because even when I was having my blood drawn, the doctor said to me, 'Is there any, you know, particular thing you're concerned about?' And I said, 'Look, I'm really f---ing tired all the time.'" Initially, Luddington thought her symptoms might be due to perimenopause, a phase before menopause. But after learning about her autoimmune diagnosis, she said, "When they said it's really common, I was like, 'well, that sucks, but okay.'" Luddington has been part of the "Grey's Anatomy" cast since 2012. In addition to her role on the ABC drama, she has starred as Kate in "William & Kate: The Movie" and appeared on shows like "Californication" and "True Blood." What to know about Hashimoto's disease Hashimoto's disease is an autoimmune disorder that can cause hypothyroidism (underactive thyroid) or, in rare cases, hyperthyroidism (overactive thyroid), according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The thyroid, a small, butterfly-shaped gland in the neck, becomes damaged in people with Hashimoto's, NIDDK states on its website. The immune system produces antibodies that attack the thyroid, leading to the accumulation of white blood cells which destroy thyroid's cells that produce hormones. 'Grey's Anatomy' renewed for 22nd season at ABC This condition is also known as Hashimoto's thyroiditis, chronic lymphocytic thyroiditis, or autoimmune thyroiditis, according to NIDDK. While the exact number of people affected in the U.S. is unknown, Hashimoto's is the leading cause of hypothyroidism, which impacts about 5% of Americans. NIDDK notes that early on, Hashimoto's may not show symptoms, but as it progresses, it can cause fatigue, weight gain, cold intolerance, joint pain, constipation, dry skin, irregular periods and a slowed heart rate. It often leads to hypothyroidism, but in its early stages, it can cause symptoms of hyperthyroidism. The thyroid may also enlarge, creating a swollen neck or goiter, which can shrink over time. According to NIDDK, the exact cause of Hashimoto's is unknown, but it is often linked to a family history of thyroid disease. Several factors, including genes, viruses like hepatitis C, certain medications, and exposure to toxins such as nuclear radiation, can contribute to its development. Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
The shocking side effects of lash serums from eye colour change to undereye circles – and alternatives to try
Eyelash and brow serums can really be hit and miss, so when you find one that works for you, you want to cling on for dear life. But what if, as it lengthens your lashes, it causes irritation and changes to your eye area? Is it worth it? There has been chatter online for a while about the side effects of prostaglandin, a common ingredient found in many really popular lash and brow serums, but the conversations around it have bubbled up once more thanks to something that Molly Mae brought up in a recent vlog. Having discovered a lash serum that has really helped lengthen and strengthen her lashes, lately she had noticed that it's potentially started to irritate her eyes. 'I have a large dilemma at the minute,' she starts, 'and talking about it is going to make it real.' She goes on to say that in her previous video, she mentioned that she has some irritation around her eyes and that they looked 'really sore', 'really irritated and dark'. Following this, she received comments from viewers stating that their lash serums had caused the same effect on their eyes. 'I've been using these serums for about eight months now,' she notes and describes them as the 'most results-driven products' she has ever used. Despite this, she started to notice irritation weeks back and, in trying to work out and connect the dots, has noted that the serums she uses for her lashes and brows contain prostaglandins, which have had some backlash because of known side effects of continued use. What is prostaglandin? Prostaglandin is an ingredient often used in hair growth supplements that, when applied topically, stimulates hair follicles to trigger growth. In the UK, it can be found readily in over-the-counter products, but in other countries, it can be prescription only, because of its potency. But just because it's potent, it doesn't make products dangerous. 'Prostaglandin-based lash serums do work,' says Dr Kemi Fabusiwa, skin doctor and medical educator, 'and that's because they mimic hormone-like substances naturally found in the body. They bind to receptors at the lash follicle, extend the growth phase, and increase the number of lashes that grow. That's why results can be so dramatic.' I love a prostaglandin-based serum – Revitalash – and have seen epic results thanks to its supercharged formula. I have never had any irritation from using it, and my hereditary dark circles were there way before I started using lash serums. What I will say, though, is that when I finish a tube of any brow or lash serum, I always break for at least a few months before using another, as I feel like it gives my lashes time to reset and just exist at a gorgeous fluttery length before I ply them with more growth juice. What are the side effects of prostaglandin? Like with any active ingredients in beauty, not everyone is going to experience adverse reactions to prostaglandin, but some side effects can be 'redness, pigmentation around the eye, or even darkening of the iris,' says Dr Fabusiwa. I have never experienced any of these side effects, but it's always good to be informed of potential reactions so you can note if something is potentially developing. Clare, our senior ecomm beauty writer, has tested many lash serums for Cosmo and has never had any adverse reactions either. Are there prostaglandin-free lash serums? Yes, there are prostaglandin-free lash serums on the market if you want to avoid the ingredient. The alternative ingredient to prostaglandin to stimulate growth, is a Peptide Lash Growth Serum £33.60 at Peptides work in a similar way but are gentler and often found in more natural serums. Because of their gentle nature, the results are slower to come and less dramatic, but great to have the option there. You Might Also Like A ranking of the very best hair straighteners - according to our Beauty Editors Best party dresses to shop in the UK right now 11 products you'd be mad to miss from the Net A Porter beauty sale
Yahoo
4 hours ago
- Yahoo
VitalHub Reports Second Quarter 2025 Results
Annual Recurring Revenue (ARR)(1) up 55% YoY to $79.6 millionTotal Revenue up 47% YoY to $23.9 millionAdjusted EBITDA(1) up 50% YoY to $6.3 million TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the 'Company' or 'VitalHub') announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three and six months ended June 30, 2025 with the Canadian securities authorities. These documents may be viewed under the Company's profile at 'Momentum continued in the second quarter with annual organic ARR(1) growth of 14% and 26% adjusted EBITDA(1) margin,' said Dan Matlow, CEO of VitalHub. 'We have worked hard to integrate all 2024 acquisitions that we are building toward our targeted consolidated financial profile. We recently closed the larger acquisitions of Canada-based Novari and UK-based Induction. These add established electronic referral, surgical wait list management, and patient engagement solutions to the VitalHub patient flow suite. Inclusive of all activity to date, we have over $40 million of cash and over $90 million of ARR(1), providing the flexibility and scale to continue expanding internationally.' VitalHub's quarterly investor conference call will take place on Friday, August 8, 2025, at 9:00AM EST. To register for the conference call please visit: Second Quarter 2025 Highlights ARR(1) as at June 30, 2025 was $79,589,081 as compared to $73,687,666 at March 31, 2025, an increase of $5,901,415 or 8%.Over the previous quarter, ARR(1) movement in Q2 2025 from Q1 2025 was attributable to the following: Organic growth of $1,860,849 or 3%. Acquisition growth of $3,870,000 or 5%. Gain of $170,566 due to fluctuations in foreign exchange rates. Revenue of $23,857,548 as compared to $16,237,605 in the equivalent prior year period, an increase of $7,619,943 or 47%. From the date of closing to June 30, 2025, Induction contributed revenue of $480,383. Gross profit as a percentage of revenue was 81% in Q2 2025 and Q2 2024. Net income before income taxes of $2,255,226 as compared to $1,383,605 in the equivalent prior year period, an increase of $871,621 or 63%. EBITDA(1) of $3,599,683 as compared to $1,972,452 in the equivalent prior year period, an increase of $1,627,231 or 82%. Adjusted EBITDA(1) of $6,304,647 or 26% of revenue, as compared to $4,193,985 or 26% of revenue in the equivalent prior year period, an increase of $2,110,662 or 50%. Six Month 2025 Highlights ARR(1) as at June 30, 2025 was $79,589,081 as compared to $51,283,570 at June 30, 2024, an increase of $28,305,511 or 55%.Over the previous year, ARR(1) movement in Q2 2025 from Q2 2024 was attributable to the following: Organic growth of $7,329,129 or 14%. Acquisition growth of $18,470,000 or 36%. Gain of $2,506,382 due to fluctuations in foreign exchange rates. Revenue of $45,532,514 as compared to $31,494,396 in the equivalent prior year period, an increase of $14,038,118 or 45%. Gross profit as a percentage of revenue was 81% in the first six months of 2025 and 2024. Net income before income taxes of $3,742,639 as compared to net income before income taxes of $3,362,500 in the equivalent prior year period, a increase of $380,139 or 11%. EBITDA(1) of $6,750,057 compared to $5,071,468 in the prior year, an increase of $1,678,589 or 33%. Adjusted EBITDA(1) of $11,919,333 or 26% of revenue, compared to $8,238,917 or 26% of revenue in the equivalent prior year period, an increase of $3,680,416 or 45%. Cash on hand as at June 30, 2025 was $94,008,665 compared to $56,574,904 as at December 31, 2024. The Company arranged a $15,000,000 loan to finance an acquisition and fully repaid the balance subsequent to quarter-end. On July 4, 2025, the Company acquired all of the issued and outstanding shares of Novari Health Inc. and its subsidiaries ('Novari') for total consideration of approximately $35.8 million in cash and the issuance of 733,726 common shares of VitalHub. Novari's platform offers a series of integrated software modules providing referral management, surgical wait list management, central intake, and care coordination. With the addition of the ARR(1) of Novari subsequent to the quarter, the Company's pro forma ARR(1) as at June 30, 2025, is approximately $91.6 million. (1) Non-IFRS measure. Disclaimers and reconciliations can be found in SEDAR filings. Selected Financial Information Three months ended Six months ended June 30,2025 %Revenue June 30,2024 %Revenue Change June 30,2025 %Revenue June 30,2024 %Revenue Change $ $ % $ $ % Revenue 23,857,548 100 % 16,237,605 100 % 47 % 45,532,514 100 % 31,494,396 100 % 45 % Cost of sales 4,499,328 19 % 3,068,801 19 % (47 %) 8,730,001 19 % 6,042,493 19 % (44 %) Gross profit 19,358,220 81 % 13,168,804 81 % 47 % 36,802,513 81 % 25,451,903 81 % 45 % Operating expenses General and administrative 4,677,904 20 % 3,260,964 20 % (43 %) 9,948,653 22 % 6,452,821 20 % (54 %) Sales and marketing 2,695,935 11 % 1,821,834 11 % (48 %) 4,724,947 10 % 3,518,298 11 % (34 %) Research and development 6,033,028 25 % 3,675,359 23 % (64 %) 11,253,211 25 % 7,093,481 23 % (59 %) Depreciation of property andequipment 250,861 1 % 81,174 0 % (209 %) 392,938 1 % 159,004 1 % (147 %) Depreciation of right-of-useassets 105,499 0 % 111,245 1 % 5 % 225,395 0 % 218,007 1 % (3 %) Share-based compensation 644,811 3 % 675,674 4 % 5 % 1,410,211 3 % 1,024,253 3 % (38 %) Deferred share-basedcompensation 90,000 0 % 0 0 % (100 %) 90,000 0 % 0 0 % (100 %) Foreign currency loss (gain) (353,294 ) (1 %) 216,662 1 % 263 % (1,047,701 ) (2 %) 148,386 0 % 806 % Other expenses (income) Amortization of intangible assets 1,437,740 6 % 1,114,299 7 % (29 %) 3,359,134 7 % 2,220,841 7 % (51 %) Business acquisition, restructuringand integration costs 1,970,153 8 % 1,199,964 7 % (64 %) 3,433,567 8 % 1,797,301 6 % (91 %) Loss on change in fair value ofcontingent consideration 0 0 % 345,895 2 % 100 % 235,498 1 % 345,895 1 % 32 % Interest expense(net of interest income) (462,564 ) (2 %) (729,595 ) (4 %) (37 %) (997,873 ) (2 %) (914,402 ) (3 %) 9 % Interest expense fromlease liabilities 12,921 0 % 11,724 0 % (10 %) 27,824 0 % 25,518 0 % (9 %) Loss on disposal ofproperty and equipment 0 0 % 0 0 % 0 % 4,070 0 % 0 0 % (100 %) Current and deferred income taxes 483,009 2 % 1,718,658 11 % (72 %) 808,950 2 % 2,379,087 8 % (66 %) Net income 1,772,217 7 % (335,053 ) (2 %) (629 %) 2,933,689 6 % 983,413 3 % 198 % EBITDA (Non-IFRS measure) 3,599,683 15 % 1,972,452 12 % 82 % 6,750,057 15 % 5,071,468 16 % 33 % Adjusted EBITDA (Non-IFRS measure) 6,304,647 26 % 4,193,985 26 % 50 % 11,919,333 26 % 8,238,917 26 % 45 % Annual recurring revenue (Non-IFRS measure) 79,589,081 51,283,570 55 % 79,589,081 51,283,570 55 % Term licences, maintenanceand support revenue 19,894,544 83 % 13,039,369 80 % 53 % 38,238,110 84 % 25,504,431 81 % 50 % As at June 30,2025 December31, 2024 $ $ Cash balance 94,008,665 56,574,904 Deferred revenue 45,303,289 35,636,002 About VitalHub VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub's comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,000 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 500 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX:VHI) (OTCQX:VHIBF), please visit and LinkedIn. Contact Information Christian Sgro, CPA, CA, CFAHead of IR and M&A Specialist(365) Dan MatlowChief Executive Officer, Director(416) Cautionary Statement Certain statements contained in this news release may constitute 'forward-looking information' or 'financial outlook' within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'is expected', 'expects', 'scheduled', 'intends', 'contemplates', 'anticipates', 'believes', 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or in to access your portfolio
